Literature DB >> 11992302

Reversibility of cirrhosis in patients cured of thalassemia by bone marrow transplantation.

Pietro Muretto1, Emanuele Angelucci, Guido Lucarelli.   

Abstract

BACKGROUND: Cirrhosis is a well-known complication of thalassemia major. In this context, it is a consequence of iron overload and hepatitis C virus infection and generally seems to be irreversible.
OBJECTIVE: To determine whether cirrhosis in thalassemia major can be reversible.
DESIGN: Retrospective study.
SETTING: Bone Marrow Transplantation Unit and Pathology Service, Pesaro Hospital, Pesaro, Italy. PATIENTS: 6 patients who developed liver cirrhosis before or after their thalassemia was cured by bone marrow transplantation (age at transplantation, 11 to 25 years). After diagnosis of cirrhosis, the patients received iron depletion and antiviral therapies. MEASUREMENTS: Each liver biopsy specimen was coded. A liver pathologist and a member of the transplantation center with expertise in hepatopathology graded the specimens by using the Ishak staging and grading systems. Neither knew the patient's identity or the sequence of biopsy with regard to the time of treatment.
RESULTS: After the patients received iron depletion and antiviral therapies, liver biopsy specimens showed impressive reduction in liver iron stores. In 4 patients, iron removal was complete. Serum aminotransferase levels decreased in all patients and normalized in 5; histologic inflammatory activity decreased in all patients and disappeared in 2. Follow-up biopsies showed regression of incomplete or definite cirrhosis in all patients; 3 patients had presented with portal fibrosis without bridging, and the others had portal fibrosis and portal-to-portal bridging. Several biopsies and the presence of many portal spaces confirmed the diagnosis of cirrhosis; follow-up biopsies confirmed regression of cirrhosis.
CONCLUSION: In some patients in whom bone marrow transplantation has cured thalassemia, cirrhosis may be reversible after iron removal treatment.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11992302     DOI: 10.7326/0003-4819-136-9-200205070-00009

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN: 0003-4819            Impact factor:   25.391


  20 in total

1.  Versican: a novel modulator of hepatic fibrosis.

Authors:  Terence N Bukong; Sean B Maurice; Barinder Chahal; David F Schaeffer; Paul J Winwood
Journal:  Lab Invest       Date:  2016-01-11       Impact factor: 5.662

2.  Hematopoietic stem cell transplantation in thalassemia major and sickle cell disease: indications and management recommendations from an international expert panel.

Authors:  Emanuele Angelucci; Susanne Matthes-Martin; Donatella Baronciani; Françoise Bernaudin; Sonia Bonanomi; Maria Domenica Cappellini; Jean-Hugues Dalle; Paolo Di Bartolomeo; Cristina Díaz de Heredia; Roswitha Dickerhoff; Claudio Giardini; Eliane Gluckman; Ayad Achmed Hussein; Naynesh Kamani; Milen Minkov; Franco Locatelli; Vanderson Rocha; Petr Sedlacek; Frans Smiers; Isabelle Thuret; Isaac Yaniv; Marina Cavazzana; Christina Peters
Journal:  Haematologica       Date:  2014-05       Impact factor: 9.941

Review 3.  NF-κB in the liver--linking injury, fibrosis and hepatocellular carcinoma.

Authors:  Tom Luedde; Robert F Schwabe
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2011-02       Impact factor: 46.802

4.  The Treatment of Hepatic Fibrosis: Reversal of the Underlying Disease Process.

Authors:  Luis Servin-Abad; Eugene R Schiff
Journal:  Gastroenterol Hepatol (N Y)       Date:  2006-11

5.  Kinetics of iron removal by phlebotomy in patients with iron overload after allogeneic hematopoietic cell transplantation.

Authors:  Ann-Kathrin Eisfeld; Rainer Krahl; Nadja Jaekel; Dietger Niederwieser; Haifa Kathrin Al-Ali
Journal:  Am J Blood Res       Date:  2012-11-25

6.  Iron increases HMOX1 and decreases hepatitis C viral expression in HCV-expressing cells.

Authors:  Wei-Hong Hou; Lisa Rossi; Ying Shan; Jian-Yu Zheng; Richard-W Lambrecht; Herbert-L Bonkovsky
Journal:  World J Gastroenterol       Date:  2009-09-28       Impact factor: 5.742

7.  Reversal of liver fibrosis.

Authors:  Mona H Ismail; Massimo Pinzani
Journal:  Saudi J Gastroenterol       Date:  2009-01       Impact factor: 2.485

Review 8.  Hepatic inflammation and progressive liver fibrosis in chronic liver disease.

Authors:  Albert J Czaja
Journal:  World J Gastroenterol       Date:  2014-03-14       Impact factor: 5.742

Review 9.  Gastrointestinal and hepatic complications of hematopoietic stem cell transplantation.

Authors:  Hande H Tuncer; Naveed Rana; Cannon Milani; Angela Darko; Samer A Al-Homsi
Journal:  World J Gastroenterol       Date:  2012-04-28       Impact factor: 5.742

10.  Regression of fibrosis in paediatric autoimmune hepatitis: morphometric assessment of fibrosis versus semiquantiatative methods.

Authors:  Ahmed F Abdalla; Khaled R Zalata; Abeer F Ismail; Gamal Shiha; Mohamed Attiya; Ahmed Abo-Alyazeed
Journal:  Fibrogenesis Tissue Repair       Date:  2009-04-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.